SE0202134D0 - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- SE0202134D0 SE0202134D0 SE0202134A SE0202134A SE0202134D0 SE 0202134 D0 SE0202134 D0 SE 0202134D0 SE 0202134 A SE0202134 A SE 0202134A SE 0202134 A SE0202134 A SE 0202134A SE 0202134 D0 SE0202134 D0 SE 0202134D0
- Authority
- SE
- Sweden
- Prior art keywords
- sup
- sub
- group
- optionally substituted
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
| TW092118207A TW200412957A (en) | 2002-07-08 | 2003-07-03 | Therapeutic agents |
| CA002491835A CA2491835A1 (en) | 2002-07-08 | 2003-07-04 | Mch1r antagonists |
| PL03374674A PL374674A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
| US10/520,372 US20060247439A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
| RU2004138079/04A RU2004138079A (ru) | 2002-07-08 | 2003-07-04 | Антагонисты рецептора-1 меланин-концентрирующего гормона (мсн1r) |
| AU2003281194A AU2003281194A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
| BR0312312-0A BR0312312A (pt) | 2002-07-08 | 2003-07-04 | Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários |
| CN038160749A CN1665502A (zh) | 2002-07-08 | 2003-07-04 | Mchir拮抗剂 |
| PCT/GB2003/002884 WO2004004726A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
| MXPA05000336A MXPA05000336A (es) | 2002-07-08 | 2003-07-04 | Antagonistas del receptor 1 de hormona de concentracion de melanina (mchir). |
| EP03740771A EP1528924A1 (en) | 2002-07-08 | 2003-07-04 | Mch1r antagonists |
| JP2004518963A JP2006501186A (ja) | 2002-07-08 | 2003-07-04 | Ｍｃｈ１ｒアンタゴニスト |
| AR20030102464A AR040476A1 (es) | 2002-07-08 | 2003-07-08 | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) |
| IL16584104A IL165841A0 (en) | 2002-07-08 | 2004-12-16 | Mchir antagonists |
| NO20045528A NO20045528L (no) | 2002-07-08 | 2004-12-17 | MHC1R-antagonister |
| ZA200500030A ZA200500030B (en) | 2002-07-08 | 2005-01-03 | MCH1r antagonists. |
| IS7653A IS7653A (is) | 2002-07-08 | 2005-01-19 | MCHIR mótlyf |
| CO05007427A CO5680403A2 (es) | 2002-07-08 | 2005-01-28 | Antagonistas de mchr1r |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0202134D0 true SE0202134D0 (sv) | 2002-07-08 |
Family
ID=20288471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060247439A1 (sv) |
| EP (1) | EP1528924A1 (sv) |
| JP (1) | JP2006501186A (sv) |
| CN (1) | CN1665502A (sv) |
| AR (1) | AR040476A1 (sv) |
| AU (1) | AU2003281194A1 (sv) |
| BR (1) | BR0312312A (sv) |
| CA (1) | CA2491835A1 (sv) |
| CO (1) | CO5680403A2 (sv) |
| IL (1) | IL165841A0 (sv) |
| IS (1) | IS7653A (sv) |
| MX (1) | MXPA05000336A (sv) |
| NO (1) | NO20045528L (sv) |
| PL (1) | PL374674A1 (sv) |
| RU (1) | RU2004138079A (sv) |
| SE (1) | SE0202134D0 (sv) |
| TW (1) | TW200412957A (sv) |
| WO (1) | WO2004004726A1 (sv) |
| ZA (1) | ZA200500030B (sv) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100451004C (zh) * | 2003-03-31 | 2009-01-14 | 大正制药株式会社 | 嘧啶衍生物 |
| EP1464335A3 (en) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
| WO2005066132A1 (en) * | 2004-01-07 | 2005-07-21 | Astrazeneca Ab | Therapeutic agents i |
| GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| CN1976905A (zh) * | 2004-03-30 | 2007-06-06 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
| WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
| US20080090863A1 (en) * | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
| AU2005316314B2 (en) * | 2004-12-17 | 2011-06-23 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| CA2636757A1 (en) | 2006-01-25 | 2007-08-02 | Tesfaye Biftu | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| ES2347193T3 (es) * | 2006-09-28 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivados de quinolina con propiedades de enlace a 5-ht. |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| CN102762575B (zh) | 2009-12-04 | 2015-04-15 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2802832A1 (en) | 2010-07-06 | 2012-01-12 | Astrazeneca Ab | Therapeutic agents 976 |
| EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN116283877A (zh) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| EA201990399A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения, композиции и их применение |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US11129807B2 (en) | 2017-02-16 | 2021-09-28 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| EA202090414A1 (ru) | 2017-08-02 | 2020-05-28 | Суновион Фармасьютикалз Инк. | Соединения и их применение |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| AU2020236225A1 (en) | 2019-03-14 | 2021-09-16 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| MX2022012833A (es) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos. |
| WO2024062089A1 (en) | 2022-09-23 | 2024-03-28 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2024062090A1 (en) | 2022-09-23 | 2024-03-28 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020283A (en) * | 1958-10-20 | 1962-02-06 | Abbott Lab | Bis-lepidines |
| WO1991018904A1 (en) * | 1990-05-30 | 1991-12-12 | American Home Products Corporation | Substituted arylsulfonamides and benzamides |
| EP0912551A1 (en) * | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| CA2330564A1 (en) * | 1998-04-29 | 1999-11-04 | John Stephen Elder | Quinolones used as mrs inhibitors and bactericides |
| DE69919707T2 (de) * | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | Glycogen synthase kinase 3 inhibitoren |
| WO2001082925A1 (fr) * | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
| JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| WO2002058702A1 (en) * | 2001-01-26 | 2002-08-01 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
-
2002
- 2002-07-08 SE SE0202134A patent/SE0202134D0/sv unknown
-
2003
- 2003-07-03 TW TW092118207A patent/TW200412957A/zh unknown
- 2003-07-04 CN CN038160749A patent/CN1665502A/zh active Pending
- 2003-07-04 EP EP03740771A patent/EP1528924A1/en not_active Withdrawn
- 2003-07-04 AU AU2003281194A patent/AU2003281194A1/en not_active Abandoned
- 2003-07-04 BR BR0312312-0A patent/BR0312312A/pt not_active IP Right Cessation
- 2003-07-04 RU RU2004138079/04A patent/RU2004138079A/ru not_active Application Discontinuation
- 2003-07-04 PL PL03374674A patent/PL374674A1/xx not_active Application Discontinuation
- 2003-07-04 JP JP2004518963A patent/JP2006501186A/ja active Pending
- 2003-07-04 US US10/520,372 patent/US20060247439A1/en not_active Abandoned
- 2003-07-04 WO PCT/GB2003/002884 patent/WO2004004726A1/en active Application Filing
- 2003-07-04 CA CA002491835A patent/CA2491835A1/en not_active Abandoned
- 2003-07-04 MX MXPA05000336A patent/MXPA05000336A/es not_active Application Discontinuation
- 2003-07-08 AR AR20030102464A patent/AR040476A1/es unknown
-
2004
- 2004-12-16 IL IL16584104A patent/IL165841A0/xx unknown
- 2004-12-17 NO NO20045528A patent/NO20045528L/no unknown
-
2005
- 2005-01-03 ZA ZA200500030A patent/ZA200500030B/en unknown
- 2005-01-19 IS IS7653A patent/IS7653A/is unknown
- 2005-01-28 CO CO05007427A patent/CO5680403A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL165841A0 (en) | 2006-01-15 |
| US20060247439A1 (en) | 2006-11-02 |
| CO5680403A2 (es) | 2006-09-29 |
| BR0312312A (pt) | 2005-04-12 |
| AR040476A1 (es) | 2005-04-06 |
| IS7653A (is) | 2005-01-19 |
| NO20045528L (no) | 2005-04-04 |
| TW200412957A (en) | 2004-08-01 |
| RU2004138079A (ru) | 2005-08-10 |
| CA2491835A1 (en) | 2004-01-15 |
| CN1665502A (zh) | 2005-09-07 |
| MXPA05000336A (es) | 2005-03-31 |
| EP1528924A1 (en) | 2005-05-11 |
| PL374674A1 (en) | 2005-10-31 |
| AU2003281194A1 (en) | 2004-01-23 |
| ZA200500030B (en) | 2005-11-11 |
| JP2006501186A (ja) | 2006-01-12 |
| WO2004004726A1 (en) | 2004-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0202134D0 (sv) | Therapeutic agents | |
| AR046186A1 (es) | Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona | |
| HUP0303148A2 (hu) | CB1 antagonista hatású 4,5-dihidro-1H-pirazol-származékok és e vegyületeket tartalmazó gyógyászati készítmények és eljárások az előállításukra | |
| MX2007006896A (es) | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. | |
| RU2008111991A (ru) | Органические соединения | |
| SE0104332D0 (sv) | Therapeutic agents | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| TW200621760A (en) | 2-morpholino-4-pyrimidone compound | |
| HRP20050708A2 (en) | Piperidine-benzenesulfonamide derivatives | |
| HUP0402107A2 (hu) | N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MX2007003722A (es) | Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la tau proteina cinasa 1. | |
| IS6459A (is) | Arýl sambrædd azapólýsýklísk efnasambönd | |
| HUP0301671A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk | |
| NO20015686L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
| EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| TW200504070A (en) | 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| MXPA05010112A (es) | Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos. | |
| HUP0203874A2 (hu) | Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények | |
| TW200635589A (en) | Therapeutic agents | |
| MX2009009121A (es) | Aminoamidas como antagonistas de orexina. | |
| MXPA05009574A (es) | Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas. | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. |